Structural Basis for Hijacking CBF-β and CUL5 E3 Ligase Complex by HIV-1 Vif

Overview

Journal Nature

Specialty Science

Date 2014 Jan 10

PMID 24402281

Citations 136

Authors

Yingying Guo

Liyong Dong

Xiaolin Qiu

Yishu Wang

Bailing Zhang

Hongnan Liu

You Yu

Yi Zang

Maojun Yang

Zhiwei Huang

Affiliations

Soon will be listed here.

Abstract

The human immunodeficiency virus (HIV)-1 protein Vif has a central role in the neutralization of host innate defences by hijacking cellular proteasomal degradation pathways to subvert the antiviral activity of host restriction factors; however, the underlying mechanism by which Vif achieves this remains unclear. Here we report a crystal structure of the Vif-CBF-β-CUL5-ELOB-ELOC complex. The structure reveals that Vif, by means of two domains, organizes formation of the pentameric complex by interacting with CBF-β, CUL5 and ELOC. The larger domain (α/β domain) of Vif binds to the same side of CBF-β as RUNX1, indicating that Vif and RUNX1 are exclusive for CBF-β binding. Interactions of the smaller domain (α-domain) of Vif with ELOC and CUL5 are cooperative and mimic those of SOCS2 with the latter two proteins. A unique zinc-finger motif of Vif, which is located between the two Vif domains, makes no contacts with the other proteins but stabilizes the conformation of the α-domain, which may be important for Vif-CUL5 interaction. Together, our data reveal the structural basis for Vif hijacking of the CBF-β and CUL5 E3 ligase complex, laying a foundation for rational design of novel anti-HIV drugs.

Citing Articles

The unique structure of the highly conserved PPLP region in HIV-1 Vif is critical for the formation of APOBEC3 recognition interfaces.

Iwatani Y, Matsuoka K, Ode H, Kubota M, Nakata Y, Setoyama Y mBio. 2025; 16(3):e0333224.

PMID: 39835817 PMC: 11898743. DOI: 10.1128/mbio.03332-24.

Variability in HIV-1 transmitted/founder virus susceptibility to combined APOBEC3F and APOBEC3G host restriction.

Gaba A, Yousefi M, Bhattacharjee S, Chelico L J Virol. 2024; 99(1):e0160624.

PMID: 39714157 PMC: 11784016. DOI: 10.1128/jvi.01606-24.

Interactions between HIV proteins and host restriction factors: implications for potential therapeutic intervention in HIV infection.

Rashid F, Zaongo S, Iqbal H, Harypursat V, Song F, Chen Y Front Immunol. 2024; 15:1390650.

PMID: 39221250 PMC: 11361988. DOI: 10.3389/fimmu.2024.1390650.

Structural insights into PPP2R5A degradation by HIV-1 Vif.

Hu Y, Delviks-Frankenberry K, Wu C, Arizaga F, Pathak V, Xiong Y Nat Struct Mol Biol. 2024; 31(10):1492-1501.

PMID: 38789685 DOI: 10.1038/s41594-024-01314-6.

Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction.

Gai Y, Duan S, Wang S, Liu K, Yu X, Yang C Viruses. 2024; 16(4).

PMID: 38675833 PMC: 11053914. DOI: 10.3390/v16040490.

References

Stopak K, de Noronha C, Yonemoto W, Greene W . HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell. 2003; 12(3):591-601. DOI: 10.1016/s1097-2765(03)00353-8. View

Chen G, He Z, Wang T, Xu R, Yu X . A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol. 2009; 83(17):8674-82. PMC: 2738209. DOI: 10.1128/JVI.00653-09. View

Zhou X, Evans S, Han X, Liu Y, Yu X . Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS One. 2012; 7(3):e33495. PMC: 3316577. DOI: 10.1371/journal.pone.0033495. View

Bullock A, Debreczeni J, Edwards A, Sundstrom M, Knapp S . Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci U S A. 2006; 103(20):7637-42. PMC: 1472497. DOI: 10.1073/pnas.0601638103. View

Zhang H, Yang B, Pomerantz R, Zhang C, Arunachalam S, Gao L . The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003; 424(6944):94-8. PMC: 1350966. DOI: 10.1038/nature01707. View

Stanley B, Ehrlich E, Short L, Yu Y, Xiao Z, Yu X . Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol. 2008; 82(17):8656-63. PMC: 2519636. DOI: 10.1128/JVI.00767-08. View

Jager S, Kim D, Hultquist J, Shindo K, LaRue R, Kwon E . Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature. 2011; 481(7381):371-5. PMC: 3310910. DOI: 10.1038/nature10693. View

Zhang H, Pomerantz R, Dornadula G, Sun Y . Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol. 2000; 74(18):8252-61. PMC: 116333. DOI: 10.1128/jvi.74.18.8252-8261.2000. View

Zimmerman E, Schulman B, Zheng N . Structural assembly of cullin-RING ubiquitin ligase complexes. Curr Opin Struct Biol. 2010; 20(6):714-21. PMC: 3070871. DOI: 10.1016/j.sbi.2010.08.010. View

10.

Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S . Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A. 2005; 102(32):11444-9. PMC: 1182177. DOI: 10.1073/pnas.0502440102. View

11.

Kim D, Kwon E, Hartley P, Crosby D, Mann S, Krogan N . CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol Cell. 2013; 49(4):632-44. PMC: 3582769. DOI: 10.1016/j.molcel.2012.12.012. View

12.

Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C . Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology. 2006; 349(2):290-9. DOI: 10.1016/j.virol.2006.02.002. View

13.

Kim Y, Kwak M, Ku B, Suh H, Joo K, Lee J . Structural basis of intersubunit recognition in elongin BC-cullin 5-SOCS box ubiquitin-protein ligase complexes. Acta Crystallogr D Biol Crystallogr. 2013; 69(Pt 8):1587-97. DOI: 10.1107/S0907444913011220. View

14.

Zhang W, Du J, Evans S, Yu Y, Yu X . T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature. 2011; 481(7381):376-9. DOI: 10.1038/nature10718. View

15.

McCoy A, Grosse-Kunstleve R, Adams P, Winn M, Storoni L, Read R . Phaser crystallographic software. J Appl Crystallogr. 2009; 40(Pt 4):658-674. PMC: 2483472. DOI: 10.1107/S0021889807021206. View

16.

Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D . Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003; 424(6944):99-103. DOI: 10.1038/nature01709. View

17.

Marin M, Rose K, Kozak S, Kabat D . HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med. 2003; 9(11):1398-403. DOI: 10.1038/nm946. View

18.

Muniz J, Guo K, Kershaw N, Ayinampudi V, von Delft F, Babon J . Molecular architecture of the ankyrin SOCS box family of Cul5-dependent E3 ubiquitin ligases. J Mol Biol. 2013; 425(17):3166-77. PMC: 3779351. DOI: 10.1016/j.jmb.2013.06.015. View

19.

Sheehy A, Gaddis N, Choi J, Malim M . Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646-50. DOI: 10.1038/nature00939. View

20.

Harris R, Bishop K, Sheehy A, Craig H, Petersen-Mahrt S, Watt I . DNA deamination mediates innate immunity to retroviral infection. Cell. 2003; 113(6):803-9. DOI: 10.1016/s0092-8674(03)00423-9. View